Ten-years outcomes of islet transplantation in patients with type 1 diabetes: data from the Swiss-French GRAGIL network

Archive ouverte

Lablanche, S. | Borot, S. | Wojtusciszyn, A. | Skaare, K. | Penfornis, A. | Malvezzi, P. | Badet, L. | Thivolet, C. | Morelon, E. | Buron, F. | Renard, E. | Tauveron, I. | Villard, O. | Munch, M. | Sommacal, S. | Clouaire, L. | Jacquet, M. | Gonsaud, L. | Camillo-Brault, C. | Colin, C. | Bosson, J. L. | Bosco, D. | Berney, T. | Kessler, L. | Benhamou, P. Y.

Edité par CCSD ; Elsevier -

International audience. To describe the 10-year outcomes of islet transplantation within the Swiss-French GRAGIL Network, in patients with type 1 diabetes experiencing high glucose variability associated with severe hypoglycemia and/or with functional kidney graft. We conducted a retrospective analysis of all subjects transplanted in the GRAGIL-1c and GARGIL-2 islet transplantation trials and analyzed components of metabolic control, graft function and safety outcomes over the 10-year period of follow-up. Forty-four patients were included between September 2003 and April 2010. Thirty-one patients completed a ten-year follow-up. Ten years after islet transplantation, median HbA1c was 7.2% [6.2-8.0] (55 mmol/mol [44-64]) vs 8.0% [7.1-9.1] (64 mmol/mol [54-76]) before transplantation (p\textless0.001). 17/23 (73.9%) recipients were free of severe hypoglycemia, 1/21 patient (4.8%) was insulin-independent and median C-peptide was 0.6 ng/ml [0.2-1.2]. Insulin requirements (UI/kg/day) were 0.3 [0.1-0.5] vs 0.5 [0.4-0.6] before transplantation (p\textless0.001). Median [IQR] β-score was 1 [0-4] (p\textless0.05 when comparing with pre-transplantation values) and 51.9% recipients had a functional islet graft at 10 years. With a 10-year follow up in a multicentric network, islet transplantation provided sustained improvement of glycemic control and was efficient to prevent severe hypoglycemia in almost 75% of the recipients.

Suggestions

Du même auteur

Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial

Archive ouverte | Lablanche, S. | CCSD

International audience. Background Islet transplantation is indicated for patients with type 1 diabetes with severe hypoglycaemia or after kidney transplantation. We did a randomised trial to assess the efficacy and...

Five-Year Metabolic, Functional, and Safety Results of Patients With Type 1 Diabetes Transplanted With Allogenic Islets Within the Swiss-French GRAGIL Network

Archive ouverte | Lablanche, S. | CCSD

International audience. OBJECTIVE: To describe the 5-year outcomes of islet transplantation within the Swiss-French GRAGIL Network. RESEARCH DESIGN AND METHODS: Retrospective analysis of all subjects enrolled in the...

Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials.

Archive ouverte | Benhamou, P. Y. | CCSD

International audience. BACKGROUND: Rigorous assessment of health-related quality of life (HRQL) is mandatory to establish the benefits of islet transplantation. METHODS: The 36-Item Short Form Health Survey (SF-36)...

Chargement des enrichissements...